Climb Bio (NASDAQ:CLYM) Trading Down 0.5% – Should You Sell?

Shares of Climb Bio, Inc. (NASDAQ:CLYM) were down 0.5% during mid-day trading on Wednesday . The company traded as low as $1.78 and last traded at $1.87. Approximately 260,564 shares were traded during mid-day trading, a decline of 59% from the average daily volume of 634,120 shares. The stock had previously closed at $1.88.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Leerink Partners initiated coverage on Climb Bio in a research report on Monday, December 2nd. They set an “outperform” rating and a $10.00 price objective on the stock. Leerink Partnrs raised shares of Climb Bio to a “strong-buy” rating in a report on Monday, December 2nd.

Climb Bio Stock Performance

The stock has a market capitalization of $125.70 million, a PE ratio of -0.88 and a beta of -0.25. The company’s 50-day moving average is $2.35.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter. As a group, equities research analysts forecast that Climb Bio, Inc. will post -1.57 EPS for the current year.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.